TD Cowen analyst Charles Rhyee maintained a Hold rating on Charles River Labs (CRL – Research Report) today and set a price target of $193.00. The company’s shares closed today at $169.47.
Rhyee covers the Healthcare sector, focusing on stocks such as Charles River Labs, Cardinal Health, and CVS Health. According to TipRanks, Rhyee has an average return of 3.6% and a 49.37% success rate on recommended stocks.
In addition to TD Cowen, Charles River Labs also received a Hold from Citi’s Patrick B Donnelly in a report issued yesterday. However, today, Deutsche Bank maintained a Buy rating on Charles River Labs (NYSE: CRL).
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $262.00 and a one-year low of $161.65. Currently, Charles River Labs has an average volume of 499.4K.
Based on the recent corporate insider activity of 71 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CRL in relation to earlier this year. Most recently, in August 2023, Barbo William D, the Corporate Executive VP & CCO of CRL sold 5,763.00 shares for a total of $1,251,954.12.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Charles River Labs (CRL) Company Description:
Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following segments: Research Models & Services, Discovery & Safety Assessment and Manufacturing Support. The Research Models & Services segment comprises of the production and sale of research models, and also offers services designed to support its client’s use of research models in screening non-clinical drug candidates. The Discovery & Safety Assessment segment offers discovery and safety assessment services, both regulated and non-regulated, in which it include both in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program management to support product development. The Manufacturing Support segment provides endotoxin and microbial detection, avian vaccine and biologics testing solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.
Read More on CRL:
